Equities

Oncotelic Therapeutics Inc

OTLC:QBB

Oncotelic Therapeutics Inc

Actions
  • Price (USD)0.024
  • Today's Change0.001 / 2.13%
  • Shares traded178.40k
  • 1 Year change-15.79%
  • Beta-0.2128
Data delayed at least 15 minutes, as of Sep 20 2024 20:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.

  • Revenue in USD (TTM)70.00k
  • Net income in USD-1.24m
  • Incorporated1992
  • Employees22.00
  • Location
    Oncotelic Therapeutics Inc29397 Agoura Road Suite 107AGOURA HILLS 91301United StatesUSA
  • Phone+1 (650) 635-7000
  • Fax+1 (650) 635-7001
  • Websitehttps://www.oncotelic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioCardia Inc428.00k-8.56m8.89m16.00------20.78-5.40-5.400.2636-0.92330.0923--6.8526,750.00-184.48-107.34-1,075.25-154.17-----1,999.77-1,779.24---------64.72-5.262.82---28.89--
Inhibikase Therapeutics Inc79.57k-18.38m8.96m8.00--1.70--112.57-2.93-2.930.01260.70630.0051----9,946.25-117.93-66.49-148.63-85.55-----23,102.16-1,139.14----0.00--111.03-42.21-5.40------
Portage Biotech Inc0.00-71.08m9.15m7.00--3.64-----68.81-68.810.002.390.00----0.00-137.29-30.53-143.21-40.02------------0.02------27.98------
Kintara Therapeutics Inc0.00-9.51m9.63m2.00---------4.08-4.080.000.10710.00----0.00-131.55-220.94-185.60-329.97------------0.00------40.24--78.93--
Plus Therapeutics Inc (USA)5.51m-13.23m9.67m20.00------1.76-3.05-3.051.19-1.340.4336----275,450.00-104.14-59.18---133.04-----240.15-470.45---4.17----2,093.30-5.8934.32--3.77--
Kazia Therapeutics Ltd (ADR)15.35k-13.93m9.67m12.00--0.9028--630.04-0.8448-0.84480.00080.35970.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Oncotelic Therapeutics Inc70.00k-1.24m9.75m22.00--0.8041--139.29-0.0031-0.00310.00020.02990.0023--3.693,181.82-5.02-25.03-11.26-48.76-----2,147.66-1,692.93---0.51670.5228-------255.12------
Check Cap Ltd0.00-17.57m9.89m85.00--0.4174-----3.00-3.000.004.050.00-------49.87-54.23-53.46-60.24------------0.00------8.06---2.46--
Jaguar Health Inc10.19m-35.67m9.89m49.00--0.4954--0.9709-41.34-41.346.622.480.17930.2317.56207,857.10-63.73-95.29-110.34-163.5479.7967.28-355.51-522.281.60-3.450.6333---18.3617.1912.97------
Virax Biolabs Group Ltd156.42k-6.73m9.94m17.00--1.17--63.55-3.35-3.350.0782.090.02053.51--9,201.18-88.11---91.88--32.34---4,308.35--25.58-227.160.0418--1,727.34---23.38------
Avalo Therapeutics Inc807.00k-36.22m10.05m19.00------12.46-63.82-63.820.3347-2.080.0122--20.9642,473.68-54.66-99.64-529.15-154.4264.1984.69-4,488.60-613.58---------89.34-22.8324.28---22.48--
Nymox Pharmaceutical Corp0.00-8.84m10.29m3.00---------0.0966-0.09660.00-0.03390.00-------785.44-306.39---749.37-------43,683.47---157.57---------34.49---39.16--
Forte Biosciences Inc0.00-35.76m10.34m11.00--0.6085-----22.03-22.030.0011.640.00----0.00-124.89-72.06-170.91-82.27-------491,850.00----0.00-------126.79---46.29--
Enzon Pharmaceuticals Inc26.00k314.00k10.45m0.0033.293.44--401.900.00420.00420.00040.62770.0006------3.39-0.86543.42-0.8851----6,111.54-159.43----0.00---100.00--106.71-55.86----
Kineta Inc0.00-20.88m10.54m11.00---------1.79-1.790.00-0.66380.00----0.00-220.35-66.16---86.61-------854.74--------178.6513.8977.76------
Yubo International Biotech Ltd454.29k-1.42m10.54m18.00------23.21-0.0118-0.01180.0038-0.02110.24620.59863.4925,238.33-82.33------80.30---334.36--0.1707-4,795.69----479.86--0.8224------
Data as of Sep 20 2024. Currency figures normalised to Oncotelic Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.